财中社11月13日电金斯瑞生物科技（01548）发布了其联营公司传奇生物科技股份有限公司截至2024年9月30日的第三季度未经审计财务业绩。传奇生物在此期间的净贸易销售额约为2.86亿美元，同比增长87.6%，环比增长53.2%。其细胞疗法CARVYKTI®成为首个显著延长多发性骨髓瘤患者总生存期的疗法，并在多个国家获得了上市批准。
在财务方面，传奇生物的许可证收入为1710万美元，合作收入为1.43亿美元，均较上年同期有所增长。同时，净亏损为1.25亿美元，较2023年同期的6220万美元有所增加。截止2024年9月30日，传奇生物的现金及现金等价物和定期存款达到12亿美元，预计能够支持其运营至2026年。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.